SCYNEXIS, Inc. (SCYX)
USD 0.9
(-1.14%)
USD 0.9
(-1.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 73.47 Million USD | 186.12% |
| 2022 | -59.9 Million USD | -38.23% |
| 2021 | -31.41 Million USD | -17.98% |
| 2020 | -51.14 Million USD | -7.57% |
| 2019 | -51.26 Million USD | -67.93% |
| 2018 | -17.09 Million USD | -11.86% |
| 2017 | -23.16 Million USD | 6.54% |
| 2016 | -29.51 Million USD | 0.7% |
| 2015 | -27.9 Million USD | -96.85% |
| 2014 | -2.19 Million USD | -36.97% |
| 2013 | -13.76 Million USD | 17.96% |
| 2012 | -9.7 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.5 Million USD | 49.98% |
| 2024 Q2 | -9.23 Million USD | -47.82% |
| 2023 Q2 | 115.4 Million USD | 1231.54% |
| 2023 Q1 | -10.19 Million USD | 53.7% |
| 2023 FY | - USD | 186.12% |
| 2023 Q4 | -22.93 Million USD | -127.13% |
| 2023 Q3 | -10.09 Million USD | -108.75% |
| 2022 Q3 | -21.51 Million USD | 1.45% |
| 2022 Q4 | -22.02 Million USD | -2.37% |
| 2022 Q1 | -19.94 Million USD | 10.95% |
| 2022 FY | - USD | -38.23% |
| 2022 Q2 | -21.83 Million USD | -9.45% |
| 2021 Q2 | -17.71 Million USD | -875.22% |
| 2021 Q1 | -1.81 Million USD | 88.4% |
| 2021 Q4 | -22.4 Million USD | -13.14% |
| 2021 Q3 | -19.79 Million USD | -11.79% |
| 2021 FY | - USD | -17.98% |
| 2020 Q2 | -12.62 Million USD | -3.23% |
| 2020 Q3 | -11.8 Million USD | 6.48% |
| 2020 Q4 | -15.65 Million USD | -32.53% |
| 2020 FY | - USD | -7.57% |
| 2020 Q1 | -12.23 Million USD | 10.95% |
| 2019 FY | - USD | -67.93% |
| 2019 Q1 | -11.5 Million USD | -35.55% |
| 2019 Q3 | -11.82 Million USD | -8.44% |
| 2019 Q4 | -13.73 Million USD | -16.21% |
| 2019 Q2 | -10.9 Million USD | 5.24% |
| 2018 FY | - USD | -11.86% |
| 2018 Q4 | -8.48 Million USD | -40.85% |
| 2018 Q3 | -6.02 Million USD | 18.43% |
| 2018 Q2 | -7.38 Million USD | -4.54% |
| 2018 Q1 | -7.06 Million USD | -0.43% |
| 2017 Q1 | -5.94 Million USD | 40.54% |
| 2017 Q2 | -6.62 Million USD | -11.42% |
| 2017 Q3 | -6.28 Million USD | 5.07% |
| 2017 Q4 | -7.03 Million USD | -11.86% |
| 2017 FY | - USD | 6.54% |
| 2016 Q4 | -10 Million USD | -369.04% |
| 2016 Q1 | -7.2 Million USD | 14.07% |
| 2016 Q3 | -2.13 Million USD | 74.51% |
| 2016 Q2 | -8.36 Million USD | -16.04% |
| 2016 FY | - USD | 0.7% |
| 2015 Q2 | -6.36 Million USD | -5.06% |
| 2015 Q1 | -6.06 Million USD | -119.96% |
| 2015 FY | - USD | -96.85% |
| 2015 Q3 | -7.53 Million USD | -18.34% |
| 2015 Q4 | -8.38 Million USD | -11.3% |
| 2014 FY | - USD | -36.97% |
| 2014 Q2 | -3.52 Million USD | -74.74% |
| 2014 Q3 | -3.5 Million USD | 0.77% |
| 2014 Q4 | -2.75 Million USD | 21.28% |
| 2014 Q1 | -2.01 Million USD | 36.03% |
| 2013 Q3 | -2.67 Million USD | -4.61% |
| 2013 FY | - USD | 17.96% |
| 2013 Q4 | -3.15 Million USD | -17.98% |
| 2013 Q1 | -1.96 Million USD | 0.0% |
| 2013 Q2 | -2.55 Million USD | -30.46% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 76.169% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 3225.423% |
| Embecta Corp. | 245.4 Million USD | 70.057% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 54.892% |
| PainReform Ltd. | -9.56 Million USD | 867.886% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2021.312% |
| Journey Medical Corporation | 1.92 Million USD | -3725.039% |
| Safety Shot Inc | -12.18 Million USD | 703.019% |
| Alpha Teknova, Inc. | -25.53 Million USD | 387.713% |
| Bright Green Corporation | - USD | -Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 29.365% |
| Alvotech | -484.86 Million USD | 115.155% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 32.785% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -6116.497% |
| Cosmos Health Inc. | -17.06 Million USD | 530.664% |
| Dynavax Technologies Corporation | 9.66 Million USD | -660.18% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 148.951% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 146.256% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2021.312% |
| Theratechnologies Inc. | -10.31 Million USD | 812.503% |
| Harrow Health, Inc. | 9.72 Million USD | -655.724% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 1723.845% |
| Biofrontera Inc. | -18.45 Million USD | 498.195% |
| DURECT Corporation | -24.68 Million USD | 397.679% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 25.221% |
| Cronos Group Inc. | -72.14 Million USD | 201.843% |
| OptiNose, Inc. | -15.55 Million USD | 572.443% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 107.945% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 303.644% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -179.748% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -103.933% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 1973.339% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 10436.78% |
| Radius Health, Inc. | 38.31 Million USD | -91.801% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 2385.456% |
| ProPhase Labs, Inc. | -14.82 Million USD | 595.576% |
| Phibro Animal Health Corporation | 84.6 Million USD | 13.153% |
| Procaps Group S.A. | 104.02 Million USD | 29.365% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 974.646% |
| Viatris Inc. | 3.51 Billion USD | 97.91% |
| Rockwell Medical, Inc. | -4.69 Million USD | 1665.381% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 7360.771% |
| SIGA Technologies, Inc. | 84.15 Million USD | 12.691% |
| Tilray Brands, Inc. | -72.84 Million USD | 200.873% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -8949.138% |
| Shineco, Inc. | -26.55 Million USD | 376.716% |
| PetIQ, Inc. | 81.48 Million USD | 9.826% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 2131.138% |
| Incannex Healthcare Limited | -18.5 Million USD | 497.098% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 82.341% |
| Alimera Sciences, Inc. | 7.27 Million USD | -909.882% |
| Silver Spike Investment Corp. | 7.34 Million USD | -901.061% |
| Assertio Holdings, Inc. | -222.44 Million USD | 133.032% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 1941.279% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 1844.569% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 537.271% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 466.83% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 149.273% |
| Hempacco Co., Inc. | -12.77 Million USD | 675.256% |
| Talphera, Inc. | -9.84 Million USD | 846.586% |
| Alvotech | -484.86 Million USD | 115.155% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 5.191% |
| Lantheus Holdings, Inc. | 491 Million USD | 85.035% |
| Currenc Group, Inc. | -1.9 Million USD | 3966.148% |
| Kamada Ltd. | 21.53 Million USD | -241.223% |
| Indivior PLC | 66 Million USD | -11.332% |
| Evoke Pharma, Inc. | -7.29 Million USD | 1107.625% |
| Flora Growth Corp. | -45.87 Million USD | 260.19% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 466.83% |
| Evolus, Inc. | -41.81 Million USD | 275.745% |
| HUTCHMED (China) Limited | 25.52 Million USD | -187.837% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 69.569% |
| Akanda Corp. | -27.73 Million USD | 364.926% |